UK markets close in 1 hour 35 minutes

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
350.35+11.09 (+3.27%)
As of 9:55AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close339.26
Open343.00
Bid347.46 x 800
Ask348.00 x 1200
Day's range341.44 - 350.89
52-week range58.81 - 464.00
Volume563,176
Avg. volume4,123,720
Market cap84.966B
Beta (5Y monthly)N/A
PE ratio (TTM)19.34
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster

    NEW YORK & MAINZ, Germany, September 23, 2021--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the Pfizer-BioNTech COVID-19 Vaccine for individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high r

  • Business Wire

    Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries

    NEW YORK & MAINZ, Germany, September 22, 2021--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to expand their agreement with the U.S. government by providing an additional 500 million doses of the companies’ COVID-19 vaccine at a not-for-profit price for donation to low- and lower-middle-income countries and the organizations that support them. This expanded agreement brings the total number of doses to be supplied to the U.S. government for donation to these countr

  • Globe Newswire

    Pfizer and BioNTech Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years

    Results are the first from a pivotal trial of any COVID-19 vaccine in children under 12 years of ageIn participants 5 to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralizing antibody responsesCompanies plan to submit these data to the FDA, EMA and other regulatory agencies around the world as soon as possibleResults in children under 5 years of age are expected as soon as later this year NEW YORK and MAINZ, Germany, September 20, 2021—Pfizer Inc. (NYSE: PFE, “Pfiz